Delving into the Latest Updates on Mupirocin Calcium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MUP, Mupirocin Calcium Hydrate, Mupirocin calcium (USP)

+ [7]

Target

IleRS

Action

inhibitors

Mechanism

IleRS inhibitors(Isoleucyl-tRNA synthetase inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

MRSA - Methicillin resistant Staphylococcus aureus infectionStaphylococcal Infections

Inactive Indication

ImpetigoStreptococcal Infections

Originator Organization

GSK Plc

Active Organization

GSK PlcGlaxoSmithKline KK

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Australia (14 Aug 1991),

Staphylococcal Infections

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H44O9

InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N

CAS Registry12650-69-0

View All Structures (2)

The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU. 2) to examine the efficacy of mupirocin in eradicating SA colonization of infants in the ICU, defined as the absence of SA in cultures of the nares, umbilical, and perianal areas on day 8 (± 2) (primary decolonization) 3) to examine the efficacy of mupirocin in achieving persistent eradication of SA colonization among infants residing in the ICU,defined as the absence of SA in cultures of the nares, umbilical, and perianal areas. Duration is 36 months. Enrolled infants will continue to receive medical care as they otherwise would if they were not enrolled in the trial. The study will be powered with a primary endpoint with 126 participants. Enrollment may continue to 500 participants to power secondary and exploratory endpoints and assist design subsequent studies.

Start Date30 Apr 2014

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Mupirocin Calcium

Login to view more data

100 Translational Medicine associated with Mupirocin Calcium

Login to view more data

100 Patents (Medical) associated with Mupirocin Calcium

Login to view more data

2,052

Literatures (Medical) associated with Mupirocin Calcium

01 Apr 2025·Materials Today Bio

Epsilon-polylysine microneedle potentiating MXene-mediated photothermal ablation for combating antibiotic-resistant bacterial infections

Article

Author: Lin, Qiaoni ; Xu, Zejun ; Quan, Guilan ; Wang, Liqing ; Luo, Rui ; Lu, Chao ; Lin, Liming ; Peng, Tingting ; Zheng, Yuwei ; Yan, Yilang ; Feng, Xiaoqian ; Xian, Dongyi ; Chi, Jiaying ; Wu, Chuanbin

Antimicrobial peptides show promise in enhancing photothermal therapy, but their application is often limited by the challenge of constructing a delivery system that balances efficacy and safety. Our research demonstrated that the bactericidal efficacy of V₂C MXene-mediated photothermal therapy is enhanced in a concentration-dependent relationship with the introduction and coating of the antimicrobial peptide ε-polylysine (EPL). EPL exhibited a dual role in enhancing bacterial binding and disrupting bacterial membranes, thereby increasing heat transfer efficiency and reducing bacterial resistance to photothermal ablation. The core strategy of this study was to exploit the combined membranolytic-photothermal effect of EPL and V₂C by extensively applying EPL while regulating V₂C nanosheets usage to prevent overheating. This approach aims to achieve potent bactericidal efficacy through photothermal therapy below 60 °C. Consequently, we developed dissolving microneedles incorporated with V₂C nanosheets, where EPL served as the antimicrobial agent and primary matrix, increasing its loading capacity and minimizing the need for inactive excipients. Notably, this microneedle achieved a 99.9 % reduction in the abundance of methicillin-resistant Staphylococcus aureus on infected skin after a single application and resulted in a 92-fold reduction in the bacterial load compared to the group treated with commercial Bactroban ointment, with no apparent toxicity to the mice.

01 Mar 2025·Journal of Hazardous Materials

Antibiotic resistome during two-stage partial nitritation/anammox process for sludge anaerobic digestion reject water treatment

Article

Author: Gong, Hui ; Zhu, Danyang ; Zhang, Yanyan ; Zhou, Shuyan ; Dai, Xiaohu

Anaerobic digestion (AD) reject water serves as a significant reservoir for antibiotic resistance genes (ARGs), underscoring the importance of understanding ARGs dynamics during treatment processes. Partial nitritation /anammox (PN/A) has become an increasingly adopted process, while comprehensive investigation on ARG behavior within this system, especially in full-scale, remains limited. This study explores the distribution of ARGs in a full-scale two-stage PN/A system, with an anaerobic/anoxic/oxic (AAO) system for comparison. The sludge in partial nitritation (PN) stage exhibited higher ARG abundance (0.82 copy/cell) compared to that in anammox stage (0.21-0.26 copy/cell). In anammox sludge samples, 95.8-99.1 % of the mobile genetic elements (MGEs) were identified as tnpA, while the PN stage showing greater diversity. Some ARGs co-occur in the same contigs, and some of these ARGs belong to different ARGs types, which is related to multi-antibiotic resistance, with the highest frequency observed in the PN stage. The abundance of contigs with ARG-MGE co-occurrence, suggesting the possibility of horizontal gene transfer (HGT), was most prevalent in the AAO system. Potential ARG hosts were identified by metagenomic binning, and some functional bacteria, like Nitrosomonas, were regarded as ARGs host. This study offers a comprehensive analysis of the complexities of ARGs distribution within full-scale two-stage PN/A systems treating AD reject water.

01 Feb 2025·Chemical Engineering Journal

Personalized design enzyme-like activity theanine coated Pt clusters for catalytic damage of bacterial and infection management

Author: Zhang, Na ; Zhang, Xiangchun ; Chen, Hongping ; Zheng, Qinqin ; Yang, Mingchuan ; Zhang, Chunyu ; Xu, Chao ; Han, Zhenduo ; Guo, Juanjuan

The formation of biofilm affords protection against host immune responses while efficiently impeding the infiltration of antibiotics and other therapeutic agents.To address these issues, the development of novel non-antibiotic antimicrobial drugs is emerging as promising solutions for combating infectious diseases.To explore inorganic metal clusters antibiotics, we have designed a theanine platinum cluster (PtCs) antibacterial agent that freely penetrates the cell wall pores to be internalized inside bacteria.This agent exhibits enhanced bioavailability, possesses peroxidase-like activity with efficient singlet oxygen (¹O₂) generation, and inhibits and destroys biofilm formation.The in vitro exptl. results demonstrate that PtCs potently inhibit bacterial growth and disrupt biofilms by catalyzing the production of reactive oxygen species (ROS).Addnl., we found that PtCs can trigger bacterial apoptosis by traversing the cell wall to enter the bacterium, where they induce DNA damage and inhibit DNA replication.In vivo study demonstrated that PtCs significantly enhance the healing of multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA) infectious wounds, and rescue mice suffering from MRSA-induced sepsis.The synthesized PtCs represent a promising candidate in the quest to combat bacterial resistance, offering significant potential for the development of novel antimicrobial strategies against bacterial infections.

100 Deals associated with Mupirocin Calcium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02195	-	R01AX06 D06AX09	DB00410

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
MRSA - Methicillin resistant Staphylococcus aureus infection	Japan	GlaxoSmithKline KK	31 Jan 1996
Staphylococcal Infections	Australia	GSK Plc	14 Aug 1991

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04155203 (CTgov)	Phase 3	Wounds and Injuries \| Infectious Diseases	657	Mupirocin Calcium (Perrigo Active)	odqsphymcr(wghvxgnmzd) = yvfonpdnfa hansrdvubi (rgdnoydmnm, vbgjhttoeb - mmlouegekg) View more	-	03 Nov 2022
				Mupirocin Calcium (Reference Active)	odqsphymcr(wghvxgnmzd) = mohogqgile hansrdvubi (rgdnoydmnm, gejzugtfqe - ibkcwzwdvr) View more
NCT04222699 (CTgov)	Phase 4	-	58	Mupirocin calcium ointment, 2%+Topical Chlorhexidine, 4%	eykvotmtfl(eenjgkprmc) = dsvwrxcson osatthqyrv (xarmslemsz, npnevxjzsl - cihvaknuri) View more	-	14 Apr 2020
NCT00626795 (CTgov)	Phase 2	Impetigo \| Wounds and Injuries	773	TD1414 (TD1414 BID)	(kxhansorqp) = cvwcycuznr qkbuiiksqv (icbiegnfpb, zfwecgnkqu - qzagtrmgxs) View more	-	23 Jul 2018
				TD1414 (TD1414 TID)	(kxhansorqp) = kznhncpmpx qkbuiiksqv (icbiegnfpb, saecxvmuqo - aqrxiqfovk) View more
NCT02029872 (SUSTAIN, CTgov)	Phase 4	-	77	Mupirocin calcium 2 % ointment+Chlorhexidine gluconate soap (Individual Alone)	yzljxypssj(qfksamgkmc) = pvjegfzbhn ninfoamzwc (qeupjolngv, qfxtnkknny - brwqfwoizm) View more	-	20 Mar 2018
				Mupirocin calcium 2 % ointment+Chlorhexidine gluconate soap (Individual Plus Household)	yzljxypssj(qfksamgkmc) = gcgygxrumt ninfoamzwc (qeupjolngv, rlenzaknzw - urwosztrvw) View more
NCT01313182 (CTgov)	Phase 4	Surgical Wound Infection	1,874	3M Skin+Nasal Antiseptic (3M Skin and Nasal Antiseptic)	bkipblknjl(jttziqmzlg) = pvjbfxabpz zitduxnkvr (toaexkieak, llxkgfrsxx - bijerpbndo) View more	-	19 May 2014
				mupirocin calcium ointment, 2% (Bactroban Nasal)	bkipblknjl(jttziqmzlg) = gspzwauhgz zitduxnkvr (toaexkieak, gysmiqpxub - ckucwysxdf) View more